The National Cancer Institute (NCI) is the largest of the National Institutes of Health’s 27 institutes and centers by appropriated budget, and the only one whose director submits a budget request directly to the President each year rather than through the standard NIH/HHS review chain — a provision known informally as the bypass budget, created by the National Cancer Act of 1971. That distinct statutory footing shows up in NCI’s funding practices too: NCI runs several mechanisms that are unique to it or NCI-flavored variants of NIH-wide instruments, and it manages its own payline separately from every other institute. This guide covers how NCI funding actually works — the payline mechanism, the mechanisms most specific to cancer research funding, and where to verify current figures. For the 2025–2026 appropriations picture sitting behind those figures — the proposed NCI reduction and what was ultimately enacted — see cancer research funding cuts in 2026.
NCI within the NIH funding structure
Like every NIH institute, NCI receives its own annual appropriation from Congress and sets its own funding priorities, application volume expectations, and payline independently of the other 26 institutes and centers — there is no single NIH-wide payline, and NCI’s figures typically diverge from institutes such as NHLBI or NIGMS in any given fiscal year. Because cancer research draws one of the largest applicant pools in the NIH system, NCI’s application volume, its funding-line dynamics, and the specific programmatic mechanisms it operates (particularly its cancer center and clinical trials network infrastructure) look different from smaller institutes in practice, even though the underlying grant mechanisms — R01, R21, K awards, F fellowships, T32 training grants, U-series cooperative agreements — are the same NIH-wide activity codes used everywhere else.
How the NCI payline works
NCI, like other institutes, converts each application’s peer-review score into a percentile rank and uses a percentile threshold — commonly called a payline, though NCI’s own materials more often describe it as part of its annual “funding strategy” — as the primary planning guideline for which R01 and R21 applications it expects to fund in a given fiscal year. As with the general NIH payline mechanism, this is a planning guideline rather than an absolute cutoff: NCI retains discretion to fund some applications above the line (for example through exception funding or bridge awards) and may not fund every application below it if the budget doesn’t stretch that far.
NCI’s payline has moved considerably in recent years, illustrating why administrators should always check the current-year figure rather than relying on a remembered number: NCI reported an 8th-percentile R01 payline in FY2019 and set a goal of raising it to the 15th percentile by FY2025. Congressional funding increases allowed NCI to raise the line to the 11th percentile in FY2022 and the 12th percentile in FY2023, before FY2024’s competing R01/R21 payline for established and new investigators settled at the 10th percentile. NCI did not publish a single fixed R01 payline for FY2025, instead awarding remaining competing applications largely in percentile order as funding allowed; for FY2025, NCI did not publish one at all, and this FY2019-FY2025 percentile progression should now be read as historical only.
FY2026 update (verified August 2026): NCI’s own current funding-policy page states directly: "In alignment with NIH funding policies, NCI no longer uses paylines to determine competing grant funding selections." Instead, NCI leaders now balance scientific merit, public health significance, scientific novelty, portfolio representation, investigator career stage, and existing NCI funding when making award decisions. For FY2026, NCI has published specific across-the-board reduction percentages that apply instead of a percentile line: new (Type 1) R01/U01 applications with direct costs of $175K or less per budget period are generally funded at a 6.5% reduction from the level recommended at peer review; those requesting more than $175K (up to $250K in at least one budget period) are generally reduced 8.5% or 17% depending on the budget tier; and new R01/U01 applications with direct costs above $250K in any budget period are generally reduced 17%. Competing renewals (Type 2s) are generally funded at the NCI Type 2 cap with no additional reduction. These are NCI-published reduction rates, not a percentile payline, and they can change again within the fiscal year — verify against NCI’s own page before using a figure in a proposal budget.
NCI publishes its current-year funding policy at cancer.gov’s funding strategy page and discusses the reasoning behind changes on its NCI Bottom Line blog. This is not a general or hedged signal at NCI specifically — it is NCI’s own explicit, current statement, part of the NIH-wide Unified Funding Strategy that NIH announced via its Extramural Nexus News page on November 21, 2025 (effective with the January 2026 council round) and that NCI has implemented on its own FY2026 funding-policy page. Source: NIH Grants & Funding, National Cancer Institute (NCI) Funding Policies and Considerations, Fiscal Year 2026, verified directly August 2026.
Funding mechanisms distinctive to NCI
P30 Cancer Center Support Grant (CCSG)
The Cancer Center Support Grant, funded through the P30 activity code, is the core infrastructure grant behind NCI’s cancer center designation program — the mechanism that funds NCI-designated cancer centers as integrated, transdisciplinary research organizations rather than collections of individual project grants. NCI designates three types of centers under this program: Comprehensive Cancer Centers (which must demonstrate strength across basic, clinical, and population-based/cancer-control research), Clinical Cancer Centers, and Basic Laboratory Cancer Centers. A CCSG renewal (Type 2) application generally requires the applicant institution to demonstrate a substantial existing base of peer-reviewed, cancer-related direct-cost funding. Initial CCSG budget periods run five years, with an additional two years available, for a maximum award period of seven years.
A distinctive administrative feature that comes with CCSG funding is the Protocol Review and Monitoring System (PRMS): NCI-designated cancer centers must maintain an institutional Scientific Review Committee (SRC) that performs upfront scientific-merit review of cancer clinical trials before they proceed to IRB review, plus ongoing monitoring of accrual, safety, and progress on already-open protocols. This SRC review is a condition of CCSG funding and is distinct from IRB review and from NIH study-section peer review of the grant application itself — three different committees, at three different points in the lifecycle, easily confused by administrators new to a cancer center environment.
R37 MERIT Award
The Method to Extend Research in Time (MERIT) Award, funded under the R37 activity code, exists NIH-wide but NCI uses it in a specific, well-defined way: converting an Early Stage Investigator’s competing R01 application into an R37 when that application scores within the NCI payline. Investigators cannot apply for a MERIT award directly — NCI program staff identify eligible ESI R01 applications and refer them to the National Cancer Advisory Board for consideration. A MERIT conversion provides up to five years of initial support with an option for an additional two years (up to seven years total) based on an expedited review of progress during the initial period, rather than requiring a full competing renewal at the standard interval. See CASRAI’s Early Stage Investigator (ESI) entry for how ESI status itself is determined.
K99/R00 and other career-stage mechanisms at NCI
NCI participates in the NIH-wide K99/R00 Pathway to Independence Award and the broader family of K-series career development awards, along with F-series individual fellowships (F31, F32) and T32 institutional training grants, on the same NIH-wide terms as other institutes, with NCI-specific program pages and staff contacts layered on top. Award budget caps and cost-of-living figures for these mechanisms are set NIH-wide (or in some cases per-institute) and should always be checked against the current fiscal-year notice rather than a prior year’s figure.
Cooperative agreements: NCTN and NCORP
Much of NCI’s clinical trials infrastructure runs through cooperative agreements (U-series activity codes) rather than standard research grants, reflecting substantial NCI programmatic involvement after award. The National Clinical Trials Network (NCTN) and the NCI Community Oncology Research Program (NCORP) are the two largest examples: NCTN funds the network of Lead Academic Participating Sites and statistical/data centers that design and run NCI-sponsored multi-site cancer clinical trials, while NCORP extends trial access into community-based oncology practices and underserved populations. Administrators supporting sites participating in either network are managing cooperative-agreement compliance obligations, not standard R01-style grant administration, even though both ultimately fund investigator-led cancer research.
SBIR/STTR at NCI
NCI operates a substantial Small Business Innovation Research (SBIR) and STTR program under the same government-wide statutory framework used across participating federal agencies, funding small businesses developing cancer-relevant technologies (diagnostics, therapeutics, devices, digital health tools) through the standard Phase I feasibility / Phase II development structure. See CASRAI’s general SBIR/STTR reauthorization guide for the statutory mechanics that apply across all participating agencies, NCI included.
Why this matters for research administrators
Grants and contracts staff supporting cancer-focused investigators or an NCI-designated cancer center need to track NCI-specific administrative layers that don’t exist at other institutes: SRC/PRMS review as a CCSG condition, the ESI-to-MERIT conversion pathway (which the investigator cannot initiate directly), and cooperative-agreement compliance for NCTN/NCORP site participation, on top of the same peer-review, NIH Grants Policy Statement, and indirect cost rules that apply NIH-wide. Because NCI’s payline and funding strategy shift from year to year — sometimes substantially, as the FY2019-FY2026 history above shows — budgeting advice given to an investigator should always be checked against NCI’s current published funding policy, not carried over from a prior cycle.
Frequently asked questions
Is the NCI payline the same as the NIH payline?
No. There is no single NIH-wide payline — each of NIH’s 27 institutes and centers, NCI included, sets its own percentile guideline independently based on its own appropriated budget, application volume, and priorities. NCI’s payline has typically differed from other large institutes such as NHLBI in any given fiscal year. See CASRAI’s general NIH Payline entry and its NHLBI Payline guide for comparison.
What is the current NCI payline?
There isn’t one. As of FY2026, NCI’s own funding-policy page states it "no longer uses paylines to determine competing grant funding selections." In place of a percentile line, NCI currently applies published across-the-board reduction percentages to new R01/U01 awards (6.5%, 8.5%, or 17% below the peer-review-recommended level, depending on requested direct costs — see above) alongside scientific merit, portfolio, and priority considerations. Always check NCI’s own current funding policy page rather than relying on a remembered or previously published percentile figure.
What is the difference between a P30 CCSG and a P01 program project grant?
A P01 (Research Program Project Grant) funds a set of interrelated research projects sharing a common scientific theme, typically within a single department or research group. A P30 Cancer Center Support Grant funds the shared infrastructure, administrative core, and institutional review mechanisms (including the SRC/PRMS described above) of an entire NCI-designated cancer center, which may itself house multiple P01s, R01s, and other individual project grants underneath it. The P30 funds the center as an organization; individual grants within it still compete and report separately.
Can an investigator apply directly for an R37 MERIT award from NCI?
No. MERIT awards are not a mechanism investigators apply to directly. NCI program staff identify eligible Early Stage Investigator R01 applications that scored within the NCI payline and refer them to the National Cancer Advisory Board for MERIT consideration; the investigator’s own action is simply submitting a strong, in-payline R01 application in the first place.
Related CASRAI resources
- NIH Payline — the general NIH-wide payline mechanism
- NHLBI Payline — how another large NIH institute publishes and applies its payline
- P01 Grant (NIH Research Program Project Grant)
- K99/R00 Grant
- Career Development (K) Awards
- Early Stage Investigator (ESI)
- Scientific Review Committee (SRC)
- Cooperative Agreement
- SBIR/STTR Reauthorization
- NIH Grants: An Overview
